Short Course Daratumumab in Patients With Multiple Myeloma
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of short course Daratumumab in combination
with lenalidomide and to find out what effects, if any, short course Daratumumab in
combination with lenalidomide has on people and their risk of multiple myeloma. The study is
also designed to test the amount of remaining myeloma cells in your body after treatment with
daratumumab which is known as minimal residual disease (MRD).